ConductScience.org, home

Comparison · NCT02067663-ebcf9c46

Mirena Group vs Paragard Group: Intrauterine Device Expulsion by 12 Weeks Postpartum

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Mirena Group vs Paragard Group: Intrauterine Device Expulsion by 12 Weeks Postpartum. Trial comparisons, record NCT02067663-ebcf9c46. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02067663-ebcf9c46

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.3820.2650.514wilson
Risk in group 20.1950.1020.34wilson
Risk difference, group 1 minus group 20.1870.0005830.348newcombe hybrid score
Risk ratio, group 1 over group 21.960.9653.97log
Odds ratio, group 1 over group 22.550.9916.55log
Number needed to treat, for one more participant with the outcome on Mirena Group than on Paragard Group5.362.871,720from the risk difference interval

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Mirena GroupWomen who have a postplacental Mirena IUD placed. (LNG-IUS)~Mirena: The IUD will be placed as part of standard clinical care.2155OG000
Group 2Paragard GroupWomen who have a postplacental Paragard IUD placed. (Copper IUD - T380A)~Paragard: The IUD will be placed as part of standard clinical care.841OG001

Outcome

Type
SECONDARY
Title
Intrauterine Device Expulsion by 12 Weeks Postpartum
Description
Position of the IUD within the uterus will be documented by ultrasound.
Time frame
12 weeks
Population

Source ClinicalTrials.gov

Trial

Title
Comparison of the Levonorgestrel IUD and the Copper IUD Placed in the Immediate Postplacental Period: A Prospective Cohort Study
NCT number
NCT02067663
Phases
Conditions
Contraception
Interventions
Paragard, Mirena
Lead sponsor
University of Colorado, Denver
Results first posted
2019-07-05

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT02067663-ebcf9c46